Lupin Gets USFDA EIR for Goa Plant

1 Minute Read Listen to Article
Share:    

Feb 27, 2026 14:01

x
Lupin receives Establishment Inspection Report (EIR) from USFDA for its Goa manufacturing facility with VAI classification.
New Delhi, Feb 27 (PTI) Drug maker Lupin on Friday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its Goa-based manufacturing facility.

The company said it has received the EIR with a satisfactory Voluntary Action Indicated (VAI) classification.

The EIR was issued following an inspection of the facility from November 10-21, 2025.


The US Food and Drug Administration (USFDA) issues an EIR on closure of inspection of an establishment that is subject of an FDA or FDA-contracted scrutiny.

"This outcome reflects our continued focus on quality excellence and regulatory compliance, reinforcing our commitment to delivering safe and effective medicines to patients worldwide," Lupin MD Nilesh Gupta said in a statement.

Shares of the company were trading 0.24 per cent up at Rs 2,328.70 apiece on BSE. PTI MSS ANU

ANU
Share:    

TODAY'S MOST TRADED COMPANIES

  • Company Name
  • Price
  • Volume

See More >

Moneywiz Live!

Home

Market News

Latest News

International Markets

Economy

Industries

Mutual Fund News

IPO News

Search News

My Portfolio

My Watchlist

Gainers

Losers

Sectors

Indices

Forex

Mutual Funds

Feedback